Nektar Therapeutics (NKTR) Stock Price Target 2026

The average analyst price target for Nektar Therapeutics is $121.38, 220.9% above the current price. Of 14 analysts, 10 rate it Buy and 4 Hold. Targets range from $50 to $192. The latest change came on Oct 12, 2026, when UBS initiated coverage of Nektar Therapeutics with a Neutral rating and a $53 price target.

The Average Analyst Price Target for Nektar Therapeutics is $121.38.

Price Target Range — 11 Quarters

Analyst Consensus — 14 Analysts

10Buy

4Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$121.38Upside to Avg. PT+220.9%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Nektar Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Neutral	$53
Oct 12, 2026	Leerink Partners	Will Soghikian	Initiate	Outperform	$130
Oct 9, 2026	BTIG	Julian Harrison	Maintained	Buy	$178
Oct 9, 2026	Raymond James	Thomas Deal	Initiate	Market Perform	—
Oct 2, 2026	HC Wainwright & Co.	Arthur He	Maintained	Buy	$185
Sep 28, 2026	BTIG	Julian Harrison	Maintained	Buy	$178
Sep 25, 2026	BTIG	Julian Harrison	Maintained	Buy	$178
Sep 23, 2026	Wedbush	Martin Fan	PT Cut	Neutral	$80→$50
Sep 16, 2026	BTIG	Julian Harrison	Maintained	Buy	$178
Sep 9, 2026	BTIG	Julian Harrison	Maintained	Buy	$178
Aug 21, 2026	JP Morgan	Jessica Fye	Reinstates	Neutral	$65
Jul 22, 2026	Canaccord Genuity	Edward Nash	Initiate	Buy	$153
May 11, 2026	Wedbush	Martin Fan	PT Cut	Neutral	$95→$80
May 8, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$105→$192
Apr 21, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$123→$151
Apr 21, 2026	Wedbush	Martin Fan	PT Raise	Neutral	$70→$95
Apr 20, 2026	HC Wainwright & Co.	Arthur He	PT Raise	Buy	$165→$185
Apr 20, 2026	BTIG	Julian Harrison	PT Raise	Buy	$151→$178
Mar 24, 2026	Wedbush	Martin Fan	Initiate	Neutral	$70
Mar 17, 2026	TD Cowen	Marc Frahm	Initiate	Buy	—

Analyst Ratings News

PRO
UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.

Benzinga Newsdesk

PRO
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $185 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.

Benzinga Newsdesk